These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
102 related items for PubMed ID: 11856249
1. The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model. MacGowan AP, Bowker KE, Wootton M, Holt HA. Clin Microbiol Infect; 1999 Apr; 5(4):195-200. PubMed ID: 11856249 [Abstract] [Full Text] [Related]
5. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. MacGowan AP, Bowker KE, Wootton M, Holt HA. Antimicrob Agents Chemother; 1999 Jul; 43(7):1560-4. PubMed ID: 10390203 [Abstract] [Full Text] [Related]
7. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. Morrissey I, Robbins M, Viljoen L, Brown DF. J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996 [Abstract] [Full Text] [Related]
9. Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Biedenbach DJ, Jones RN, Pfaller MA, Sentry Participants Group (Americas and Europe). Diagn Microbiol Infect Dis; 2001 Apr; 39(4):245-50. PubMed ID: 11404068 [Abstract] [Full Text] [Related]
12. Efficacy and safety of moxifloxacin for community-acquired bacterial pneumonia based on pharmacokinetic analysis. Yoshida K, Okimoto N, Kishimoto M, Fukano H, Hara H, Yoneyama H, Moriya O, Kawanishi M, Kimura M, Matsushima T, Niki Y. J Infect Chemother; 2011 Oct; 17(5):678-85. PubMed ID: 21847518 [Abstract] [Full Text] [Related]
13. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF. Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194 [Abstract] [Full Text] [Related]
14. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis? Pottumarthy S, Sader HS, Fritsche TR, Jones RN. Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168 [Abstract] [Full Text] [Related]
15. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. Hoban D, Felmingham D. J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228 [Abstract] [Full Text] [Related]
16. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China. Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y. Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692 [Abstract] [Full Text] [Related]